Friday, 16 October 2026European Markets

BAM GROEP KON Stock Bullish Momentum With A 17.41% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with BAM GROEP KON (BAMNB.AS) rising 17.41% to €2.99 on Thursday while AEX-Index jumped 0.46% to €847.59.

BAM GROEP KON's last close was €2.55, 10.53% under its 52-week high of €2.85.

About BAM GROEP KON

Koninklijke BAM Groep nv, together with its subsidiaries, provides products and services in the construction and property, civil engineering, and public private partnerships (PPP) sectors worldwide. The company engages in civil engineering, residential construction projects and non-residential construction activities. It is also involved in rail infrastructure and facilities management activities. In addition, the company engages in roads, education, health care, and government building construction related businesses. Koninklijke BAM Groep nv was founded in 1869 and is headquartered in Bunnik, the Netherlands.

Earnings Per Share

As for profitability, BAM GROEP KON has a trailing twelve months EPS of €0.56.

PE Ratio

BAM GROEP KON has a trailing twelve months price to earnings ratio of 5.35. Meaning, the purchaser of the share is investing €5.35 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.15%.

Moving Average

BAM GROEP KON's worth is way higher than its 50-day moving average of €2.52 and way higher than its 200-day moving average of €2.14.

Volatility

BAM GROEP KON's last week, last month's, and last quarter's current intraday variation average was a negative 0.67%, a negative 0.07%, and a positive 1.27%.

BAM GROEP KON's highest amplitude of average volatility was 2.49% (last week), 1.38% (last month), and 1.27% (last quarter).

More news about BAM GROEP KON (BAMNB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com